776 related articles for article (PubMed ID: 3747639)
1. A biological marker, strongly associated with early oral contraceptive use, for the selection of a high risk group for premenopausal breast cancer.
Olsson H; Borg A; Ewers SB; Fernö M; Möller T; Ranstam J
Med Oncol Tumor Pharmacother; 1986; 3(2):77-81. PubMed ID: 3747639
[TBL] [Abstract][Full Text] [Related]
2. Permanent alterations induced in plasma prolactin and estrogen receptor concentration in benign and malignant tissue of women who started oral contraceptive use at an early age.
Olsson H; Lindahl B; Ranstam J; Borg A; Fernö M; Norgren A
Anticancer Res; 1987; 7(4B):853-6. PubMed ID: 3674773
[TBL] [Abstract][Full Text] [Related]
3. Hormone serum levels and hormone receptor contents of endometria in women with normal menstrual cycles and patients bearing endometrial carcinoma.
Spona J; Ulm R; Bieglmayer C; Husslein P
Gynecol Obstet Invest; 1979; 10(2-3):71-80. PubMed ID: 535775
[TBL] [Abstract][Full Text] [Related]
4. Pituitary and ovarian function in women receiving hormonal contraception.
Cohen BL; Katz M
Contraception; 1979 Nov; 20(5):475-87. PubMed ID: 393456
[TBL] [Abstract][Full Text] [Related]
5. Influence of menstrual cycle, parity and oral contraceptive use on steroid hormone receptors in normal breast.
Battersby S; Robertson BJ; Anderson TJ; King RJ; McPherson K
Br J Cancer; 1992 Apr; 65(4):601-7. PubMed ID: 1562470
[TBL] [Abstract][Full Text] [Related]
6. Sex hormone profiles in oligomenorrheic adolescent girls and the effect of oral contraceptives.
Siegberg R; Nilsson CG; Stenman UH; Widholm O
Fertil Steril; 1984 Jun; 41(6):888-93. PubMed ID: 6233177
[TBL] [Abstract][Full Text] [Related]
7. Early oral contraceptive use as a prognostic factor in breast cancer.
Olsson H; Möller TR; Ranstam J; Borg A; Fernö M
Anticancer Res; 1988; 8(1):29-32. PubMed ID: 3358638
[TBL] [Abstract][Full Text] [Related]
8. Blood prolactin levels: influence of age, menstrual cycle and oral contraceptives.
Pansini F; Bianchi A; Zito V; Mollica G; Cavallini AR; Candini GC; Bagni B; Bergamini C; Bassi P
Contraception; 1983 Sep; 28(3):201-7. PubMed ID: 6641222
[TBL] [Abstract][Full Text] [Related]
9. Oral contraceptives, postmenopausal oestrogen-progestagen use and breast cancer.
Gambrell RD
J Obstet Gynaecol (Lahore); 1984 Apr; 4(Suppl 2):S121-7. PubMed ID: 12339859
[TBL] [Abstract][Full Text] [Related]
10. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
[TBL] [Abstract][Full Text] [Related]
11. Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel.
Gaspard UJ; Romus MA; Gillain D; Duvivier J; Demey-Ponsart E; Franchimont P
Contraception; 1983 Jun; 27(6):577-90. PubMed ID: 6225622
[TBL] [Abstract][Full Text] [Related]
12. Pituitary-ovarian relationships preceding the menopause. I. A cross-sectional study of serum follice-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels.
Reyes FI; Winter JS; Faiman C
Am J Obstet Gynecol; 1977 Nov; 129(5):557-64. PubMed ID: 910845
[TBL] [Abstract][Full Text] [Related]
13. Effects of combined oral contraceptive steroids on pituitary-ovarian function during the menstrual cycle of lactating women.
Ryu K; Yu HK; Kwak HM; Hong SS
Contraception; 1983 Mar; 27(3):299-310. PubMed ID: 6406140
[TBL] [Abstract][Full Text] [Related]
14. Importance of progesterone in DNA synthesis of pregnancy-dependent mammary tumors in mice.
Yanai R; Nagasawa H
Int J Cancer; 1976 Sep; 18(3):317-21. PubMed ID: 986372
[TBL] [Abstract][Full Text] [Related]
15. Ovarian function is effectively inhibited by a low-dose triphasic oral contraceptive containing ethinylestradiol and levonorgestrel.
Gaspard UJ; Dubois M; Gillain D; Franchimont P; Duvivier J
Contraception; 1984 Apr; 29(4):305-18. PubMed ID: 6430638
[TBL] [Abstract][Full Text] [Related]
16. Plasma levels of adrenocorticotropin and cortisol in women receiving oral contraceptive steroid treatment.
Carr BR; Parker CR; Madden JD; MacDonald PC; Porter JC
J Clin Endocrinol Metab; 1979 Sep; 49(3):346-9. PubMed ID: 224073
[TBL] [Abstract][Full Text] [Related]
17. Cyclic fluctuations in human serum lipid and apolipoprotein levels during the normal menstrual cycle: comparison with changes occurring during oral contraceptive therapy.
Lussier-Cacan S; Xhignesse M; Desmarais JL; Davignon J; Kafrissen ME; Chapdelaine A
Metabolism; 1991 Aug; 40(8):849-54. PubMed ID: 1907348
[TBL] [Abstract][Full Text] [Related]
18. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency.
Knopp RH; Walden CE; Wahl PW; Hoover JJ; Warnick GR; Albers JJ; Ogilvie JT; Hazzard WR
J Clin Endocrinol Metab; 1981 Dec; 53(6):1123-32. PubMed ID: 7298796
[TBL] [Abstract][Full Text] [Related]
19. The effect of transdermal oestradiol on bleeding pattern, hormonal profiles and sex steroid receptor distribution in the endometrium of Norplant users.
Boonkasemsanti W; Reinprayoon D; Pruksananonda K; Niruttisard S; Triratanachat S; Leepipatpaiboon S; Wannakrairot P
Hum Reprod; 1996 Oct; 11 Suppl 2():115-23. PubMed ID: 8982753
[TBL] [Abstract][Full Text] [Related]
20. Gonadotropin, prolactin, and steroid hormone levels after discontinuation of oral contraceptives.
Klein TA; Mishell DR
Am J Obstet Gynecol; 1977 Mar; 127(6):585-9. PubMed ID: 842583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
